Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 58 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC MOST POPULAR Rescue Cat Alerts Mom to Breast Cancer by “Aggressively” Cuddling Her... May 11, 2021 Νέα για τον καρκίνο του προστάτη June 9, 2019 COVID-19 Is Decimating Nursing Homes, So GreaterGood Has Donated Masks To... May 8, 2020 Connecting and Celebrating December 23, 2020 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab Mom Wants Disney To Ban Childless Adults From Their Theme Parks Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with... Trastuzumab May Improve Survival in Women with Rare Endometrial Cancer
